180 Life Sciences Corp

180 Life Sciences Corp is a clinical-stage biotechnology company focused on developing novel therapeutics for inflammatory diseases, fibrosis, and pain. The company advances multiple product platforms in mid- to late-stage development, including a fibrosis and anti-TNF platform targeting fibrotic disease processes and inflammatory TNF signaling, a Synthetic Cannabidiol analogs platform comprising man-made derivatives of cannabidiol, and an α7 nicotinic acetylcholine receptor (α7nAChR) platform exploring receptor-mediated approaches. Headquartered in Menlo Park, California, 180 Life Sciences collaborates with leading academic researchers from institutions such as Oxford University, Hebrew University, and Stanford University to leverage multidisciplinary expertise in drug discovery and development. The company aims to fulfill unmet medical needs by identifying and developing therapies that address inflammation, scarring, and pain, potentially advancing treatments through mid-to-late-stage clinical trials.